drugset / Trial / NCT06029595

Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

NCT06029595

Phase 2 Terminated 517 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)

Timeline

Start
2023-11-26
Primary completion
2025-12-09
Completion
2025-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TRANIMILAST Small molecule 3200 ug Inhaled

Indications